Torben F. Ørntoft

32.4k citations

261 papers · 23.0k indexed · 2 hit papers · h-index 76

Molecular Biology top 0.1%
Cancer Research top 0.05%
Surgery top 0.5%
Oncology top 0.5%
Pulmonary and Respiratory Medicine top 0.5%

Co-authors: Claus L. Andersen Jens Ledet Jensen Lars Dyrskjøt Mogens Kruhøffer Hans Wolf Michael Borre Thomas Thykjær Karin Birkenkamp‐Demtröder
Topics: Bladder and Urothelial Cancer Treatments (55 papers)Genetic factors in colorectal cancer (36 papers)Epigenetics and DNA Methylation (36 papers)
Cited by: Cancer Research Molecular Biology Oncology
Journals: Nature Journal of Biological Chemistry Nature Communications
Partner nations: Denmark United States Germany

In The Last Decade

Torben F. Ørntoft

260 papers receiving 22.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets

2004 5.9k citations Claus L. Andersen, Jens Ledet Jensen et al. Cancer Research profile →
An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes

2017 353 citations Christa Haldrup, Jesper B. Bramsen et al. profile →

Peers

Countries citing papers authored by Torben F. Ørntoft

Since Specialization

Citations

This map shows the geographic impact of Torben F. Ørntoft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben F. Ørntoft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben F. Ørntoft more than expected).

Fields of papers citing papers by Torben F. Ørntoft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torben F. Ørntoft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben F. Ørntoft. The network helps show where Torben F. Ørntoft may publish in the future.

Co-authorship network of co-authors of Torben F. Ørntoft

This figure shows the co-authorship network connecting the top 25 collaborators of Torben F. Ørntoft. A scholar is included among the top collaborators of Torben F. Ørntoft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torben F. Ørntoft. Torben F. Ørntoft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial 2020 ·PLoS Medicine ·Jacob Fredsøe,(unknown),Peter Vedsted,Pia Kirkegaard,Michael Væth,Adrian Edwards,Torben F. Ørntoft,Karina D. Sørensen,Flemming Bro	9
2	Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study 2018 ·BMC Family Practice ·Pia Kirkegaard,Adrian Edwards,(unknown),Torben F. Ørntoft,Karina D. Sørensen,Michael Borre,Flemming Bro	7
3	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer 2017 ·Clinical Cancer Research ·Lone V. Schøler,Thomas Reinert,Mai‐Britt W. Ørntoft,(unknown),Sigrid S. Árnadóttir,Søren Vang,Iver Nordentoft,Michael Knudsen,Philippe Lamy,Ditte Andreasen,Frank Viborg Mortensen,Anders Riegels Knudsen,Katrine Stribolt,Kim Sivesgaard,Peter Mouritzen,Hans Jørgen Nielsen,Søren Laurberg,Torben F. Ørntoft,Claus L. Andersen	230
4	Identifying aggressive prostate cancer foci using a DNA methylation classifier 2017 ·Genome biology ·Kamilla Mundbjerg,Sameer Chopra,Mehrdad Alemozaffar,Christopher E. Duymich,Ranjani Lakshminarasimhan,Peter W. Nichols,Manju Aron,Kimberly D. Siegmund,Osamu Ukimura,Monish Aron,Mariana C. Stern,Parkash S. Gill,John D. Carpten,Torben F. Ørntoft,Karina D. Sørensen,Daniel J. Weisenberger,Peter A. Jones,Vinay Duddalwar,Inderbir S. Gill,Gangning Liang	43
5	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma 2016 ·Cancer Research ·Philippe Lamy,Iver Nordentoft,Karin Birkenkamp‐Demtröder,Mathilde Borg Houlberg Thomsen,Palle Villesen,Søren Vang,Jakob Hedegaard,Michael Borre,Jørgen Bjerggaard Jensen,S. Høyer,Jakob Skou Pedersen,Torben F. Ørntoft,Lars Dyrskjøt	68
6	Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy 2014 ·Clinical Cancer Research ·Helle Kristensen,Christa Haldrup,Siri H. Strand,Kamilla Mundbjerg,Martin M. Mortensen,Kasper Thorsen,Marie S. Ostenfeld,Peter J. Wild,Christian Arsov,Wolfgang Goering,Tapio Visakorpi,Lars Egevad,Johan Lindberg,Henrik Grönberg,S. Høyer,Michael Borre,Torben F. Ørntoft,Karina D. Sørensen	73
7	A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine 2013 ·Clinical Cancer Research ·Raju Kandimalla,Roy Masius,Willemien Beukers,Chris H. Bangma,Torben F. Ørntoft,Lars Dyrskjøt,Nikki van Leeuwen,Hester F. Lingsma,Angela A.G. van Tilborg,Ellen C. Zwarthoff	51
8	Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer 2012 ·American Journal Of Pathology ·Niels Fristrup,Karin Birkenkamp‐Demtröder,Thomas Reinert,Marta Sänchez‐Carbayo,Ulrika Segersten,Per‐Uno Malmström,Joan Palou,M. Álvarez-Múgica,Chin‐Chen Pan,Benedicte Parm Ulhøi,Michael Borre,Torben F. Ørntoft,Lars Dyrskjøt	67
9	Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro 2009 ·Cancer Research ·Lars Dyrskjøt,Marie S. Ostenfeld,Jesper B. Bramsen,Asli Silahtaroglu,Philippe Lamy,Ramshanker Ramanathan,Niels Fristrup,Jens Ledet Jensen,Claus L. Andersen,Karsten Zieger,Sakari Kauppinen,Benedicte Parm Ulhøi,Jørgen Kjems,Michael Borre,Torben F. Ørntoft	315
10	Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy 2009 ·Clinical Cancer Research ·Karina D. Sørensen,Peter J. Wild,Ashkan Mortezavi,(unknown),Niels Tørring,Sara Heebøll,Benedicte Parm Ulhøi,Peter D. Ottosen,Tullio Sulser,Thomas Hermanns,Holger Moch,Michael Borre,Torben F. Ørntoft,Lars Dyrskjøt	25
11	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer 2009 ·Clinical Cancer Research ·Robert N. Jorissen,Peter Gibbs,Michael Christie,Saurabh Prakash,Lara Lipton,Jayesh Desai,Rachel Kerr,Lauri A. Aaltonen,Diego Arango,Mogens Kruhøffer,Torben F. Ørntoft,Claus L. Andersen,Mike Gruidl,Vidya Kamath,Steven A. Eschrich,Timothy J. Yeatman,Oliver M. Sieber	343
12	Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer 2008 ·Cancer Research ·Troels Schepeler,Thomas Reinert,Marie S. Ostenfeld,Lise L. Christensen,Asli Silahtaroglu,Lars Dyrskjøt,Carsten Wiuf,Frank J. Sørensen,Mogens Kruhøffer,Søren Laurberg,Sakari Kauppinen,Torben F. Ørntoft,Claus L. Andersen	419
13	DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers 2008 ·Clinical Cancer Research ·Robert N. Jorissen,Lara Lipton,Peter Gibbs,Matthew Chapman,Jayesh Desai,Ian T. Jones,Timothy J. Yeatman,Philip East,Ian Tomlinson,Hein W. Verspaget,Lauri A. Aaltonen,Mogens Kruhøffer,Torben F. Ørntoft,Claus L. Andersen,Oliver M. Sieber	75
14	p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest 2008 ·Cancer Research ·Christian Braun,Xin Zhang,(unknown),Sonja Wolff,Ute M. Moll,Troels Schepeler,Torben F. Ørntoft,Claus L. Andersen,Matthias Dobbelstein	388
15	High-Density Single Nucleotide Polymorphism Array Defines Novel Stage and Location-Dependent Allelic Imbalances in Human Bladder Tumors 2005 ·Cancer Research ·Karen Koed,Carsten Wiuf,Lise-Lotte Christensen,Friedrik P. Wikman,Karsten Zieger,(unknown),Hans von der Maase,Torben F. Ørntoft	68
16	Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors 2005 ·Clinical Cancer Research ·Karsten Zieger,Lars Dyrskjøt,Carsten Wiuf,Jens Ledet Jensen,Claus L. Andersen,Klaus Møller‐Ernst Jensen,Torben F. Ørntoft	76
17	A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome 2005 ·Clinical Cancer Research ·Lars Dyrskjøt,Karsten Zieger,Mogens Kruhøffer,Thomas Thykjær,Jens Ledet Jensen,Hanne Primdahl,Natasha Aziz,Niels Marcussen,(unknown),Torben F. Ørntoft	108
18	Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Setsbreakdown → 2004 ·Cancer Research ·Claus L. Andersen,Jens Ledet Jensen,Torben F. Ørntoft	5912
19	Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins 2004 ·Cancer Research ·(unknown),Monica Fedele,Sabrina Battista,Francesca Pentimalli,Mogens Kruhøffer,Claudio Arra,Torben F. Ørntoft,Carlo M. Croce,Alfredo Fusco	40
20	A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. 2001 ·PubMed ·(unknown),Boe Sandahl Sørensen,Steen Seier Poulsen,Torben F. Ørntoft,Hans Wolf,Ebba Nexø	99

About Torben F. Ørntoft

Torben F. Ørntoft is a scholar working on Cancer Research, Pathology and Forensic Medicine and Molecular Biology, having authored 261 papers that have together received 23.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (55 papers), Genetic factors in colorectal cancer (36 papers) and Epigenetics and DNA Methylation (36 papers). The work is most often cited by research in Cancer Research (7.0k citations), Molecular Biology (15.0k citations) and Oncology (3.5k citations). Torben F. Ørntoft has collaborated with scholars based in Denmark, United States and Germany. Frequent co-authors include Claus L. Andersen, Jens Ledet Jensen, Lars Dyrskjøt, Mogens Kruhøffer, Hans Wolf, Michael Borre, Thomas Thykjær, Karin Birkenkamp‐Demtröder, Karina D. Sørensen and Søren Laurberg. Their work appears in journals such as Nature, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact